Janarthanan Sathananthan, Stephanie Sellers, Aaron M Barlow, Viktória Stanová, Rob Fraser, Stefan Toggweiler, Keith B Allen, Adnan Chhatriwalla, Dale J Murdoch, Mark Hensey, Karen Lau, Abdullah Alkhodair, Danny Dvir, Anita W Asgar, Anson Cheung, Philipp Blanke, Jian Ye, Régis Rieu, Phillippe Pibarot, David Wood, Jonathan Leipsic, John G Webb
OBJECTIVES: The authors assessed the effect of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) followed by bioprosthetic valve fracture (BVF), testing different transcatheter heart valve (THV) designs in an ex vivo bench study. BACKGROUND: Bioprosthetic valve fracture can be performed to improve residual transvalvular gradients following VIV TAVR. METHODS: The authors evaluated VIV TAVR and BVF with the SAPIEN 3 (S3) (Edwards Lifesciences, Irvine, California) and ACURATE neo (Boston Scientific Corporation, Natick, Massachusetts) THVs...
January 14, 2019: JACC. Cardiovascular Interventions